David Hyman, MD
Amultihistology basket study proved the targetability of the AKT1 E17K
mutation in human cancers by treating patients with various types of cancer harboring an AKT1 E17K
mutation with AZD5363, an oral pan-AKT inhibitor, according to findings published in the Journal of Clinical Oncology. 1
The PI3K/AKT pathway is one of the most frequently activated pathways across cancers and can be triggered by one of several mutations.
Table. Primary tumor location of enrolled patients1
Once treatment commenced, patient disease was assessed and analyzed at baseline, every 6 weeks for 6 months, then every 12 weeks until any occurrence of a significant change in progression or withdrawal. The primary endpoint of this study was safety; response according to RECIST v1.1 criteria and progression-free survival (PFS) were key secondary endpoints.
... to read the full story